Antibodies Against Chlamydia trachomatis and Ovarian Cancer Risk in Two Independent Populations

Pelvic inflammatory disease (PID) has been associated with ovarian cancer risk. To clarify the role of Chlamydia trachomatis and other infectious agents in the development of ovarian cancer, we evaluated the association of serologic markers with incident ovarian cancer using a staged approach in two...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:JNCI : Journal of the National Cancer Institute Ročník 111; číslo 2; s. 129
Hlavní autoři: Trabert, Britton, Waterboer, Tim, Idahl, Annika, Brenner, Nicole, Brinton, Louise A, Butt, Julia, Coburn, Sally B, Hartge, Patricia, Hufnagel, Katrin, Inturrisi, Federica, Lissowska, Jolanta, Mentzer, Alexander, Peplonska, Beata, Sherman, Mark E, Wills, Gillian S, Woodhall, Sarah C, Pawlita, Michael, Wentzensen, Nicolas
Médium: Journal Article
Jazyk:angličtina
Vydáno: United States 01.02.2019
Témata:
Adult
Aged
Antibodies, Bacterial - blood
Antibodies, Bacterial - immunology
Antigens, Bacterial - immunology
Bacterial Proteins - immunology
Case-Control Studies
Chlamydia Infections - complications
Chlamydia Infections - immunology
Chlamydia trachomatis - immunology
Female
Follow-Up Studies
Humans
Middle Aged
Ovarian Neoplasms - epidemiology
Ovarian Neoplasms - etiology
Ovarian Neoplasms - pathology
Poland - epidemiology
Prognosis
Prospective Studies
Risk Factors
United States - epidemiology
Young Adult
Poland
United States
ISSN:1460-2105, 1460-2105
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Pelvic inflammatory disease (PID) has been associated with ovarian cancer risk. To clarify the role of Chlamydia trachomatis and other infectious agents in the development of ovarian cancer, we evaluated the association of serologic markers with incident ovarian cancer using a staged approach in two independent populations. Studies included: 1) a case-control study in Poland (244 ovarian cancers/556 control subjects) and 2) a prospective nested case-control study in the PLCO Cancer Screening Trial (160 ovarian cancers/159 control subjects). Associations of serologic marker levels with ovarian cancer risk at diagnostic as well as higher thresholds, identified in Poland and independently evaluated in PLCO, were estimated using multivariable adjusted logistic regression. In the Polish study, antibodies (based on laboratory cut-point) against the chlamydia plasmid-encoded Pgp3 protein (serological gold standard) were associated with increased ovarian cancer risk (adjusted odds ratio [OR] = 1.63, 95% confidence interval [CI] = 1.20 to 2.22); when a positive result was redefined at higher levels, ovarian cancer risk was increased (cut-point 2: OR = 2.00, 95% CI = 1.38 to 2.89; cut-point 3 [max OR]: OR = 2.19, 95% CI = 1.29 to 3.73). In the prospective PLCO study, Pgp3 antibodies were associated with elevated risk at the laboratory cut-point (OR = 1.43, 95% CI = 0.78 to 2.63) and more stringent cut-points (cut-point 2: OR = 2.25, 95% CI = 1.07 to 4.71); cut-point 3: OR = 2.53, 95% CI = 0.63 to 10.08). In both studies, antibodies against other infectious agents measured were not associated with risk. In two independent populations, antibodies against prior/current C. trachomatis (Pgp3) were associated with a doubling in ovarian cancer risk, whereas markers of other infectious agents were unrelated. These findings lend support for an association between PID and ovarian cancer.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1460-2105
1460-2105
DOI:10.1093/jnci/djy084